Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Company profile
Ticker
VRTX
Exchange
Website
CEO
Reshma Kewalramani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vertex Pharmaceuticals (San Diego) LLC • Vertex Securities Corporation • Vertex Pharmaceuticals (Distribution) Incorporated • Vertex Pharmaceuticals (Cayman) Limited • Vertex Pharmaceuticals (Cayman III) Limited • Vertex Pharmaceuticals (Cayman 509) Limited • Vertex Pharmaceuticals (Cayman 765) Limited • Vertex Pharmaceuticals (Cayman 787) Limited • Vertex Pharmaceuticals (Delaware) LLC • Vertex Pharmaceuticals (Puerto Rico) LLC ...
IRS number
43039129
VRTX stock data
News

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft
1 Jul 22
Why Jim Cramer Prefers Devon Energy Over EOG Resources
23 Jun 22
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
17 Jun 22
Vectrus Shareholders Approve Combination with Vertex; Co. Will Be Renamed V2X, To Trade On NYSE Under Ticker VVX
15 Jun 22
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
13 Jun 22
Press releases
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
14 Jun 22
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
11 Jun 22
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
10 Jun 22
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
8 Jun 22
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
8 Jun 22
Analyst ratings and price targets
Current price
Average target
$281.71
Low target
$242.00
High target
$325.00
Argus Research
Maintains
$280.00
Cowen & Co.
Maintains
$310.00
Maxim Group
Upgraded
$325.00
SVB Leerink
Initiated
$265.00
Piper Sandler
Maintains
$242.00
Morgan Stanley
Upgraded
$250.00
Wells Fargo
Maintains
$300.00
Calendar
6 May 22
2 Jul 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jun 22 | Kewalramani Reshma | Common Stock | Sell | Dispose S | No | Yes | 291.3 | 11,689 | 3.41M | 111,153 |
31 May 22 | Bozic Carmen | Common Stock | Payment of exercise | Dispose F | No | No | 271.24 | 311 | 84.36K | 49,512 |
18 May 22 | Upadhyay Suketu | Common Stock | Grant | Acquire A | No | No | 0 | 1,558 | 0 | 1,558 |
16 May 22 | Joy Liu | Common Stock | Sell | Dispose S | No | Yes | 254.36 | 35 | 8.9K | 14,334 |
16 May 22 | Joy Liu | Common Stock | Sell | Dispose S | No | Yes | 253.87 | 34 | 8.63K | 14,369 |
16 May 22 | Joy Liu | Common Stock | Sell | Dispose S | No | Yes | 252.49 | 20 | 5.05K | 14,403 |
16 May 22 | Joy Liu | Common Stock | Sell | Dispose S | No | Yes | 251.57 | 19 | 4.78K | 14,423 |
16 May 22 | Joy Liu | Common Stock | Sell | Dispose S | No | Yes | 250.77 | 25 | 6.27K | 14,442 |
Institutional ownership, Q1 2022
90.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1034 |
Opened positions | 145 |
Closed positions | 114 |
Increased positions | 400 |
Reduced positions | 360 |
13F shares | Current |
---|---|
Total value | 59.94B |
Total shares | 231.68M |
Total puts | 3.14M |
Total calls | 2.06M |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 23.92M | $6.24B |
Vanguard | 20.47M | $5.34B |
FMR | 13.18M | $3.44B |
Capital World Investors | 12.67M | $3.31B |
STT State Street | 12.05M | $3.15B |
Alliancebernstein | 10.56M | $2.75B |
Wellington Management | 8.05M | $2.1B |
Loomis Sayles & Co L P | 6.39M | $1.67B |
TROW T. Rowe Price | 5.3M | $1.38B |
Clearbridge Advisors | 5.15M | $1.34B |
Financial report summary
?Competition
Sarepta Therapeutics • Sangamo Therapeutics • Reata Pharmaceuticals • Dicerna Pharmaceuticals • Evotec SE • Agios Pharmaceuticals • Yumanity Therapeutics • Calithera Biosciences • Xenon Pharmaceuticals • Avidity BiosciencesRisks
- Risks Related to Our Business
- Risks Related to Development and Clinical Testing of Our Products and Product Candidates
- Risks Related to Government Regulation
- Risks Related to Business Development Activities
- Risks Related to Supply, Manufacturing and Reliance on Third Parties
- Risks Related to Intellectual Property
- Risks Related to Our Operations
- Risks Related to Financial Results and Holding Our Common Stock
- We invest significant resources in the research and development of therapies for serious diseases other than CF, and if we are unable to successfully commercialize one or more of these therapies, our business could be materially harmed.
- All of our product revenues and the vast majority of our total revenues are derived from sales of medicines for the treatment of CF. If we are unable to continue to increase revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline.
- If our competitors bring products with superior product profiles to market, our products may not be competitive and our revenues could decline.
- If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval or sales could be suspended, and our business could be materially harmed.
- If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would be materially harmed in future periods.
- Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed.
- We may experience incremental pricing pressure on our products, which could reduce our revenues and future profitability.
- Current health care laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. health care system may affect our ability to commercialize our marketed products profitably.
- We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products.
- We have limited experience developing and commercializing cell and genetic therapies and could experience challenges with these programs, which could result in delays or prevent the development, manufacturing and commercialization of our cell and genetic therapies.
- We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of, or significant reduction in sales to, these customers would adversely affect our results of operations.
- Our product candidates remain subject to clinical testing and regulatory approval, and our future success is dependent on our ability to successfully develop additional product candidates for both CF and non-CF indications.
- If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays in commercialization, or be unable to commercialize our product candidates.
- If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected.
- Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.
- If regulatory authorities interpret any of our conduct, including our marketing practices, as being in violation of applicable health care laws, including fraud and abuse laws, laws prohibiting off-label promotion, disclosure laws or other similar laws, we may be subject to civil or criminal penalties.
- If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines that could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
- If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates.
- We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation.
- If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
- Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities.
- We may not realize the anticipated benefits of acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management.
- We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates.
- We may not be able to attract collaborators or external funding for the development and commercialization of certain of our product candidates.
- We depend on third-party manufacturers and our internal capabilities to manufacture our products and the materials we require for our clinical trials. We may not be able to maintain our third-party relationships and could experience supply disruptions outside of our control.
- We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements.
- If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products or substantial liabilities.
- Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes that are inherently costly and unpredictable.
- We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- Risks associated with operating in foreign countries could materially adversely affect our business.
- If we fail to attract and retain skilled employees, our business could be materially harmed.
- We are subject to risks associated with the COVID-19 pandemic.
- If we fail to manage our operations effectively, our business may suffer.
- Our business faces potential risks relating to the U.K.’s withdrawal from the E.U.
- Our business has a substantial risk of product liability claims and other litigation liability.
- A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business.
- If our facilities were to experience a catastrophic loss, our operations would be seriously harmed.
- The use of social media platforms presents risks and challenges.
- Our stock price may fluctuate.
- Our effective tax rate fluctuates, and changes in tax laws, regulations and treaties, unfavorable resolution of tax contingencies or exposure to additional income tax liabilities could have a material impact on our future taxable income.
- Our quarterly operating results are subject to significant fluctuation.
- We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock.
- We may need to raise additional capital that may not be available.
- Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business, reducing our operational flexibility and creating default risks.
- Issuances of additional shares of our common stock could cause the price of our common stock to decline.
- There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices.
- We have adopted anti-takeover provisions and are subject to Massachusetts corporate laws that may frustrate any attempt to remove or replace our current management or effectuate a business combination involving Vertex.
- SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have four approved medicines to treat cystic fibrosis, or CF, a life-threatening genetic disease, and are focused on increasing the number of people with CF eligible and able to receive our medicines through label expansions, approval of new medicines, and expanded reimbursement. We are broadening our pipeline into additional disease areas through internal research efforts and accessing external innovation through business development transactions.
- Our triple combination regimen, TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are being used by the majority of the approximately 83,000 people with CF in North America, Europe, and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for approximately 90% of people with CF. We also are pursuing genetic therapies for the remaining people with CF who may not be helped by our current CF medicines.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adapt, addressing, biological, biology, build, commensurate, deduct, distribute, document, dystrophin, expression, fifteen, folding, gene, Healthcare, hypoimmune, improved, internationally, Job, lack, mid, modified, muscle, NaV, network, pediatric, perioperative, pursuit, randomized, restoration, restoring, scale, Scheme, secretion, sNDA, spanning, stability, study
Removed:
abuse, adequate, administer, allocate, altogether, April, ASU, chemical, chronic, claimed, conform, contemplated, correct, corrector, Corrupt, culture, Cut, Darmstadt, deciding, demonstrate, denied, deny, devote, dilutive, discrete, discretion, diversifying, dosage, driven, earn, edit, efficacy, eliminate, England, establish, evidence, excluding, expand, false, FASB, fetal, foster, France, fraud, fraudulent, gathered, genetically, Germany, GILTI, govern, harmed, hematopoietic, hemoglobin, high, illegal, impairment, implantation, implementation, important, indefinite, induce, inside, Intangible, investigated, involved, Ireland, jurisdiction, KGaA, knowingly, low, manufacturer, Medicaid, medically, Medicare, Merck, method, Misfolded, misfolding, musculoskeletal, neuropathic, offer, oncology, originate, person, pertaining, phased, physical, preceding, prescription, privacy, prohibiting, promotion, proper, protection, proteinuria, red, reduction, referral, registration, regulate, reinvestment, remuneration, repatriation, replace, requesting, retained, return, root, safe, side, solicit, stringent, subjected, system, systemic, Taxed, territorial, Topic, transplant, transplantation, unapproved, unnecessary, uptake, validated, variety, willfully, withholding, worldwide, write
Financial reports
Current reports
8-K
Other Events
23 May 22
8-K
Submission of Matters to a Vote of Security Holders
18 May 22
8-K
Vertex Reports First Quarter 2022 Financial Results
4 May 22
8-K
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
26 Jan 22
8-K
Vertex Reports Third-Quarter 2021 Financial Results
2 Nov 21
8-K
Vertex Reports Second-Quarter 2021 Financial Results
29 Jul 21
8-K
Other Events
24 Jun 21
8-K
Submission of Matters to a Vote of Security Holders
19 May 21
8-K
Vertex Reports First-Quarter 2021 Financial Results
29 Apr 21
8-K
Entry into a Material Definitive Agreement
20 Apr 21
Registration and prospectus
S-3ASR
Automatic shelf registration
9 Feb 22
S-8
Registration of securities for employees
1 Aug 19
S-8
Registration of securities for employees
1 Aug 19
S-3ASR
Automatic shelf registration
13 Feb 19
S-8
Registration of securities for employees
26 Jul 18
S-8
Registration of securities for employees
27 Jul 17
S-3ASR
Automatic shelf registration
2 May 16
S-8
Registration of securities for employees
3 Aug 15
S-8
Registration of securities for employees
15 Jul 14
S-8
Registration of securities for employees
20 May 13
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 22
PX14A6G
Letter to shareholders
29 Apr 21
DEFA14A
Additional proxy soliciting materials
8 Apr 21
PX14A6G
Letter to shareholders
1 Jun 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
PX14A6G
Letter to shareholders
21 May 19
Other
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
2 Apr 18
CT ORDER
Confidential treatment order
12 Jun 17
CT ORDER
Confidential treatment order
6 Apr 17
UPLOAD
Letter from SEC
16 Feb 17
NO ACT
No action letter
9 Feb 17
CT ORDER
Confidential treatment order
8 Feb 17
CORRESP
Correspondence with SEC
6 Feb 17
CORRESP
Correspondence with SEC
15 Dec 16
UPLOAD
Letter from SEC
4 Dec 16
Ownership
4
VERTEX PHARMACEUTICALS INC / MA / Reshma Kewalramani ownership change
28 Jun 22
4
VERTEX PHARMACEUTICALS INC / MA / Carmen Bozic ownership change
2 Jun 22
4
VERTEX PHARMACEUTICALS INC / MA / Suketu Upadhyay ownership change
19 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Bastiano Sanna ownership change
18 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Stuart A Arbuckle ownership change
18 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Joy Liu ownership change
18 May 22
3
VERTEX PHARMACEUTICALS INC / MA / Suketu Upadhyay ownership change
18 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Bastiano Sanna ownership change
6 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Stuart A Arbuckle ownership change
4 May 22
4
VERTEX PHARMACEUTICALS INC / MA / Bastiano Sanna ownership change
4 May 22
Patents
Utility
Methods of Treatment for Cystic Fibrosis
16 Jun 22
Inventors: Bartlomiej Borek, Weichao George Chen, Rudy Gunawan, Eric Haseltine, Nitin Nair, Porntula Panorchan, Patrick Sosnay
Utility
Compositions and Methods for Treatment of Disorders Associated with Repetitive DNA
16 Jun 22
Compositions and methods for treating excising trinucleotide repeats, as well as for treating diseases and disorders associated with trinucleotide repeats are encompassed.
Utility
Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
14 Jun 22
Inventors: Licong Jiang, Sara Sabina Hadida Ruah
Utility
Macroencapsulation Devices
9 Jun 22
The present disclosure relates to macroencapsulation devices and related methods of manufacture where the membranes of a device may be mounted to an associated frame in a relaxed, or slack, configuration prior to filling with a desired material.
Utility
Methods of preparing inhibitors of influenza viruses replication
31 May 22
Inventors: Gerald J. Tanoury, William Aloysius Nugent, Vadims Dvornikovs, Peter Jamison Rose
Transcripts
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
27 Jan 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
30 Jul 21
2021 Q1
Earnings call transcript
30 Apr 21
2020 Q4
Earnings call transcript
2 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
30 Jul 20
2020 Q1
Earnings call transcript
29 Apr 20
2019 Q4
Earnings call transcript
31 Jan 20
Reddit threads
Daily General Discussion and Advice Thread - July 02, 2022
2 Jul 22
r/Stocks Daily Discussion & Fundamentals Friday Jul 01, 2022
1 Jul 22
r/Stocks Daily Discussion Wednesday - Jun 29, 2022
29 Jun 22
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
Immunotherapy, Cancer Treatments, and Genomics ETF's and Stock picks
12 Jun 22
Give me a company and I will make a Discounted Cash Flow (DCF) model.
7 Jun 22
r/Stocks Daily Discussion & Technicals Tuesday - May 31, 2022
31 May 22
This is not looking good. Also I know I need to switch brokers. I’m mostly invested in tech stocks but any good companies to add to climb out of this faster?
25 May 22
r/Stocks Daily Discussion & Technicals Tuesday - May 24, 2022
24 May 22
$CBIO up over 100% on news it’s selling a chunk of its portfolio to $VRTX for 60mm
23 May 22